Fed. Circ. Affirms PTAB Ax Of AbbVie's Humira Patent
The Federal Circuit on Tuesday summarily affirmed the Patent Trial and Appeal Board's inter partes review decisions invalidating a key patent for AbbVie Biotechnology Ltd.'s top-selling Humira, an immunosuppressant drug that...To view the full article, register now.
Already a subscriber? Click here to view full article